Get the Stockscreener App
102.30
3.23%
3.20
After Hours:
102.30
Nuvalent Inc stock is traded at $102.30, with a volume of 629.91K.
It is up +3.23% in the last 24 hours and up +20.17% over the past month.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$99.10
Open:
$98.6
24h Volume:
629.91K
Relative Volume:
1.36
Market Cap:
$7.17B
Revenue:
-
Net Income/Loss:
$-145.51M
P/E Ratio:
-55.30
EPS:
-1.85
Net Cash Flow:
$-111.41M
1W Performance:
+0.24%
1M Performance:
+20.17%
6M Performance:
+36.24%
1Y Performance:
+122.54%
1-Day Range:
$98.60
$102.96
1-Week Range:
$98.60
$104.90
52-Week Range:
$41.16
$113.51
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
Perceptive Advisors LLC Sells 234,377 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
Nuvalent's SWOT analysis: promising cancer drug stock faces pivotal year By Investing.com - Investing.com UK
Nuvalent, Inc. (NASDAQ:NUVL) Shares Sold by D. E. Shaw & Co. Inc. - MarketBeat
Driehaus Capital Management LLC Boosts Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
Nuvalent director Shair sells over $200k in company stock By Investing.com - Investing.com South Africa
Nuvalent director Shair sells over $200k in company stock By Investing.com - Investing.com Australia
Nuvalent director Shair sells over $200k in company stock - Investing.com
Nuvalent director Shair sells over $200k in company stock By Investing.com - Investing.com UK
Profund Advisors LLC Sells 4,915 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Fred Alger Management LLC Has $43.86 Million Position in Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
Samlyn Capital LLC Makes New Investment in Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
Samlyn Capital LLC Purchases Shares of 229,325 Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
Nuvalent’s $575 Million Common Stock Offering - Global Legal Chronicle
Nuvalent (NASDAQ:NUVL) Shares Down 5% - MarketBeat
Nuvalent: Promising Data Keeps Validating Pipeline And Platform (NASDAQ:NUVL) - Seeking Alpha
HighVista Strategies LLC Sells 31,313 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
Edgestream Partners L.P. Takes $1.19 Million Position in Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
Objective long/short (NUVL) Report - Stock Traders Daily
Nuvalent (NASDAQ:NUVL) Trading 3.3% Higher - MarketBeat
Upstream enters IPO queue; Nuvalent follow-on balloons to $575M - BioCentury
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally? - MSN
Nuvalent Inc [NASDAQ: NUVL] Sees Increase in Stock Value - Knox Daily
Nuzee Inc (NUZE) Stock: A Year of Declines and Increases - The InvestChronicle
Breaking down NUZE’s current quarter earnings estimates - US Post News
Nuvalent Announces Upsized $575M Public Offering of Common Stock - WilmerHale
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates - Zacks Investment Research
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates - Yahoo Finance
Nuzee, Inc. Announces Endorsement Agreement Between Macanuoli and Five Sports Champions - PR Newswire
NUVB: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Nuvalent (NASDAQ:NUVL) Shares Gap Down to $112.17 - Defense World
Nuvalent chief scientific officer sells over $3.2 million in stock By Investing.com - Investing.com Australia
Nuvation Bio Inc [NUVB] Records 200-Day SMA of $2.56 - Knox Daily
Nucor (NYSE:NUE) Price Target Cut to $170.00 by Analysts at Morgan Stanley - Defense World
Nuvalent chief scientific officer sells over $3.2 million in stock - Investing.com India
Nuvalent (NASDAQ:NUVL) Lifted to “Strong Sell” at The Goldman Sachs Group - Defense World
Nuvalent Announces Closing of Upsized Public Offering of Common Stock - The Malaysian Reserve
Nautilus Biotechnology senior VP sells shares worth over $99k - Investing.com India
Nuvalent chief legal officer sells over $770k in company stock - Investing.com Australia
Nuvalent chief legal officer sells over $770k in company stock - Investing.com India
Nuvalent chief scientific officer sells over $3.2 million in stock By Investing.com - Investing.com Canada
Nuvalent chief scientific officer sells over $3.2 million in stock - Investing.com
Nuvalent chief scientific officer sells over $3.2 million in stock By Investing.com - Investing.com UK
Nuvalent chief legal officer sells over $770k in company stock - Investing.com UK
Nuvalent Announces Closing of Upsized Public Offering of Common Stock - Financial Times
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally? - Yahoo Finance
A new trading data show Nuvalent Inc (NUVL) is showing positive returns. - SETE News
FY2025 EPS Estimates for Nuvalent, Inc. (NASDAQ:NUVL) Cut by Leerink Partnrs - MarketBeat
Nuvalent (NASDAQ:NUVL) Stock Rating Upgraded by The Goldman Sachs Group - MarketBeat
Rhumbline Advisers Purchases 7,420 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent (NASDAQ:NUVL) PT Raised to $105.00 - Defense World
Wedbush Increases Nuvalent (NASDAQ:NUVL) Price Target to $115.00 - Defense World
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):